[
  {
    "ts": null,
    "headline": "Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited",
    "summary": "Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited (\"Biocon\") for the sale of Viatris' equity stake in Biocon Biologics Limited (\"Biocon Biologics\"). Under the definitive agreements, Biocon will acquire all of Viatris' convertible preferred equity in Biocon Biologics for total consideration of $815 million, consisting of $400 million in cash and $415 million in newly issued equity shares of Biocon.",
    "url": "https://finnhub.io/api/news?id=b9628aa12ff2017fd314b7dd38e1e60fca4ecc4c4b15e7453f7a1d6da1a51e10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765029600,
      "headline": "Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited",
      "id": 137726775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited (\"Biocon\") for the sale of Viatris' equity stake in Biocon Biologics Limited (\"Biocon Biologics\"). Under the definitive agreements, Biocon will acquire all of Viatris' convertible preferred equity in Biocon Biologics for total consideration of $815 million, consisting of $400 million in cash and $415 million in newly issued equity shares of Biocon.",
      "url": "https://finnhub.io/api/news?id=b9628aa12ff2017fd314b7dd38e1e60fca4ecc4c4b15e7453f7a1d6da1a51e10"
    }
  }
]